Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
Date:10/27/2008

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.

The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF).

The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall Institute (WEHI) that antagonism of G-CSF or its receptor could ameliorate inflammatory conditions such as rheumatoid arthritis.

Under the terms of the restructure, CSL will now take full control of the program, including development and commercialisation of any potential drugs arising from the program. In return, MuriGen will receive certain payments - the details of which are undisclosed.

Dr Nick Samaras, MuriGen's Chief Executive Officer, said, "We are extremely pleased that the further development of the G-CSF inflammatory disease program will be conducted by an Australian biopharmaceutical partner with the expertise and capability that CSL provide. This partnership is another major milestone for MuriGen and is further evidence of the high quality portfolio the company has in-licensed from the Walter and Eliza Hall Institute. MuriGen will continue to focus on its other programs, including the development of a novel class of antiapoptotic compounds."

"This is an important step in the translation of the Institute's intellectual property," explains Dr Julian Clark, Head of Business Development at WEHI. Clark continues, "Starfish Ventures' investment in MuriGen enabled us to bring this project to a stage where CSL can now use their considerable resources and track record to progress development towards the c
'/>"/>

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Resilinc released online today its ... summarizes and analyzes nearly 700 unique supply chain notifications ... global event monitoring and alert reporting service. Supply chain ... period of the email service to receive early warnings ... impact revenue, market share, customer satisfaction, and shareholder value. ...
(Date:3/2/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... biosimilar therapeutics, today announced that it will be ... in Miami, FL at the Loews Miami Beach Hotel.  Dr. ... Pfenex, will provide an overview of the company,s ... ET. A live audio webcast and archive of ...
(Date:3/2/2015)... BARBARA, Calif. , March 2, 2015 /PRNewswire/ ... biotechnology company developing therapies for autoimmune and infectious ... Office (USPTO) has issued an important new composition ... system function through the targeting of CLIP. ... targeted peptide technology underlying VG Life Sciences, VG1177, ...
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
Breaking Biology Technology:Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 2Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 3VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3
... AMEX: SNT ) announced that that Leslie J. ... DATE: December 1, 2011 TIME: 10:00 AM EST LINK: ... now" button. This will be a live, interactive ... questions in real-time both in the presentation hall as well ...
... Molecular Devices, LLC, the prominent source of powerful ... release of a much-anticipated customizable extension to its suite ... (Logo:  http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ) Version ... the 51st annual meeting of the American Society for ...
... lead roles in a study that identified a portion ... embryonic stem cells (hESCs). The study was a worldwide ... of Sheffield (UK), Paul Robson of the Genome Institute ... Institute (BTI), and Barbara Knowles and others in the ...
Cached Biology Technology:Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st 2Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st 3Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow 2Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow 3Singapore scientists lead human embryonic stem cell study 2Singapore scientists lead human embryonic stem cell study 3
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... has been the inspiration for countless books and movies, ... engineers. Researchers at the California Institute of Technology (Caltech) ... intelligencenot in a robot or a silicon chip, but ... to have made an artificial neural network out of ...
... Mobile devices have become as common as the stethoscope in ... read test results, access diagnostic tools and take patient notes, ... smartphone or using a flash drive. These mobile devices are ... huge security risks to patient information. In less ...
... LOS ALAMOS, New Mexico, July 20, 2011Researchers at the ... Great Lakes Bioenergy Research Center have found a potential ... materials such as corn leaves and stalks, or switch ... Journal of the American Chemical Society , Los Alamos ...
Cached Biology News:Caltech researchers create the first artificial neural network out of DNA 2Caltech researchers create the first artificial neural network out of DNA 3Caltech researchers create the first artificial neural network out of DNA 4Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 2Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 3Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 4Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 5Researchers find potential key for unlocking biomass energy 2
... PGE2 is one of several isoprostanes produced from ... potent renal vasoconstrictor in the rat. 8-iso PGE2 ... values of 0.5 and 5 µM, respectively. When ... at a concentration of 4 mg/kg/min, 8-iso PGE2 ...
... Source: Tritirachium album Description: Proteinase ... used in a wide range of applications purified ... bonds mainly following the carboxyl group of N-substituted ... and is classified as a serine protease. Proteinase ...
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: